Purple Biotech (PPBT) Net Income towards Common Stockholders (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Net Income towards Common Stockholders data on file, last reported at $86000.0 in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 81.02% year-over-year to $86000.0 in Q1 2026; TTM through Mar 2026 was $26.0 million, a 560.91% increase from a year earlier, with the FY2025 full-year figure at -$26.4 million, down 264.45% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $86000.0, down from $23.5 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for PPBT reached as high as $23.5 million in Q4 2025 and fell as low as $86000.0 in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged $4.4 million across 5 years, with a median of $3.8 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders plunged 91.51% in 2024 and surged 5642.93% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $6.0 million in 2022, then slipped by 19.68% to $4.8 million in 2023, then plunged by 91.51% to $410000.0 in 2024, then jumped by 5642.93% to $23.5 million in 2025, then sank by 99.63% to $86000.0 in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $86000.0 in Q1 2026, $23.5 million in Q4 2025, and $1.3 million in Q3 2025.